Navigation Links
Statement from the Consumer Healthcare Products Association on Today's FDA Advisory Committee Meeting on the Efficacy of Phenylephrine in the 10 Mg Oral Dose
Date:12/14/2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/12/2008)...The Westaim Corporation,announced today that for t... a net loss of $6.9 million or 7 cents per share, ...ast year, the company recorded a net,loss of $6.7 ... million., Income from continuing operations was ...ion in the same period last year. The results incl...
(Date:5/12/2008)...r drugs may help prevent heart attacks during surg...ajor stroke, says a major study to be published on... Lancet. , POISE is the worlds largest randomize...ions. POISE evaluated the effects of a beta-block...e of surgery. , POISE demonstrates that a beta-...
(Date:5/12/2008)...eart, of System, WASHINGTON, May 12 /PRNewswire... (VA), the nation,s largest single employer of nur...f its top professionals., "VA nurses are the co...system," stated Secretary of Veterans Affairs Dr. ...mes from the personal, one-on-one interaction,betw...
(Date:5/12/2008)...PAREXEL International,Corporation (Nasdaq: PRXL )...rt W. Baird 2008 Growth Stock Conference in Chicag... and Chief Financial Officer will be making,a form...ursday, May 15,2008., A live webcast of this pre...Relations Webcasts" section of PAREXEL,s web site ...
Breaking Medicine News(10 mins):Health News:Westaim announces 2008 first quarter results 2Health News:Westaim announces 2008 first quarter results 3Health News:Metoprolol around the time of surgery increases the risk of death and stroke: POISE trial 2Health News:Metoprolol around the time of surgery increases the risk of death and stroke: POISE trial 3Health News:PAREXEL International to Present at Robert W. Baird's 2008 Growth Stock Conference 2
...d, 66, who had a heart transplant at Papworth Hosp...n Sunday following a short illness. He was Britai...aving survived for 26 years after undergoing the s..., was also diagnosed with cardiomyopathy and had a...
...lth authorities Tuesday warned consumers against t...as Endopile Capsules.// The Health Sciences Autho...mplaint, had revealed harmful amounts of lead and ...een recalled from the Singapore market. The HSA sa...
...cids is claimed to prevent more sudden deaths than... implanted defibrillators according to US scientis... Minn., compared such preventive strategies by foo...vices in a computer-simulated community of 100,000...
...nds that two-thirds of the people in the US do not...ouncil that had been newly formed had conducted th...s reported that the participants had been chosen f...y, Germany, United Arab Emirates, India, Malaysia,...
Other Medicine News:
(Date:5/12/2008)...esults show promising neurological recovery in sev...jury patients treated with Cethrin, HOPKINTON, Ma...maceuticals, Inc. (Nasdaq: ALSE ) today announced...al trial of Cethrin, a proprietary recombinant,pro...to restore motor and,sensory function after spinal...
(Date:5/12/2008)... PHILADELPHIA, May 12 /PRNewswire-USNewswire/ -- G...east International Group (BIG), a leading,academic...mber groups, the,Spanish Breast Cancer Cooperative...bal Phase III study that will examine the role of ... Neo-ALTTO (Neoadjuvant Lapatinib and/or,Trastuzum...
(Date:5/9/2008)... TAMPA, Fla., May 9 /PRNewswire-USNewswire/ -- Man...ide effects. These can include nausea and,vomiting..., chronic use.,Such symptoms can lead patients to ...ions to pain management for physicians. The novel ... acting oral analgesic, provided pain,relief for p...
(Date:5/9/2008)... Fifth International Phase III Study Shows Positiv... Data -, NUTLEY, N.J., May 9 /- Ro...o-year Phase III study showing that ACTEMRA(TM),(t...of structural damage to,joints in patients with rh...ectiveness of an RA treatment. The study also demo...
Breaking Medicine Technology:Alseres Pharmaceuticals Announces 12 Month Interim Results from the Phase I/IIa Cethrin(R) Clinical Trial in Acute Spinal Cord Injury 2Alseres Pharmaceuticals Announces 12 Month Interim Results from the Phase I/IIa Cethrin(R) Clinical Trial in Acute Spinal Cord Injury 3Alseres Pharmaceuticals Announces 12 Month Interim Results from the Phase I/IIa Cethrin(R) Clinical Trial in Acute Spinal Cord Injury 4Alseres Pharmaceuticals Announces 12 Month Interim Results from the Phase I/IIa Cethrin(R) Clinical Trial in Acute Spinal Cord Injury 5TYKERB(R) (Lapatinib) to be Investigated in Landmark Early Breast Cancer Trial 2TYKERB(R) (Lapatinib) to be Investigated in Landmark Early Breast Cancer Trial 3TYKERB(R) (Lapatinib) to be Investigated in Landmark Early Breast Cancer Trial 4TYKERB(R) (Lapatinib) to be Investigated in Landmark Early Breast Cancer Trial 5TYKERB(R) (Lapatinib) to be Investigated in Landmark Early Breast Cancer Trial 6TYKERB(R) (Lapatinib) to be Investigated in Landmark Early Breast Cancer Trial 7New Study Suggests Tapentadol IR for Acute Pain Is Associated With Improved Gastrointestinal Tolerability Compared to Oxycodone IR 2New Study Suggests Tapentadol IR for Acute Pain Is Associated With Improved Gastrointestinal Tolerability Compared to Oxycodone IR 3New Study Suggests Tapentadol IR for Acute Pain Is Associated With Improved Gastrointestinal Tolerability Compared to Oxycodone IR 4New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients 2New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients 3New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients 4New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients 5Boehringer Ingelheim Pharmaceuticals Inc Receives the NCQA Seal Of Approval 3381 1Boehringer Ingelheim Pharmaceuticals Inc Receives the NCQA Seal Of Approval 3381 2Martek Signs Multi Year Sole Source Supply Agreement with Numico 3379 1Martek Signs Multi Year Sole Source Supply Agreement with Numico 3379 2Arthritis sufferers fund arthritis research 12211 1WeissComm Partners Names Tom Jones Managing Director to Deepen Global Product Communications Offering 12209 1WeissComm Partners Names Tom Jones Managing Director to Deepen Global Product Communications Offering 12209 2
... BLOOMFIELD, N.J., July 05, 2007 /PRNewswire/ -- A...A. Kenyon, executive vice,president, chief financi...n overview of the company,s product development pr...t the C.E. Unterberg,Towbin Emerging Growth Oppor...lide presentation will be available live at,<a tar...
... REHOVOT, Israel and NORTH BRUNSWICK, New Jersey, ...nomics Ltd , a leading microRNA,company, announced...esident, will present at CE Unterberg, Towbin Emer...uly 10, at 11:00 am EST at,the Mandarin Oriental H...esentation will be available on,the "Investors" se...
Other Medicine Technology:Alfacell Corporation to Present at C.E. Unterberg, Towbin Emerging,Growth Opportunities Conference 2Rosetta Genomics to Webcast Presentation at CE Unterberg, Towbin,Emerging Growth Opportunities Conference 2
DUALSWITCH-SHUNTSYSTEM for L-P-Derivation
14 cm, very delicate, round cupped jaws, straight jaws, 3.0 mm
Bateman pituitary forceps, round cup, 5 mm bite, fenestrated crocodile jaws, 150 mm effective.
Spetzler titanium microsurgical instrument. Small spatula dissector, bayonet, angled up 30°.
Medicine Products: